Ipsen withdrew tazemetostat worldwide for follicular lymphoma and epithelioid sarcoma after new trial data suggested a less favorable safety profile than previously characterized. SYMPHONY-1 ...

Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik® (tazemetostat) in ...

Synovial sarcoma, a rare cancer, thrives on glutamine. Blocking its nutrient supply with the drug V9302 stops tumor growth, offering a new way to treat the disease.

Synovial sarcoma is an aggressive malignant tumor that primarily affects the limbs of teenagers and young adults. While it can be cured if completely removed by surgery, recurrence or metastasis, the ...

Synovial sarcoma is an aggressive malignant tumor that primarily affects the limbs of teenagers and young adults. While it can be cured if completely removed by surgery, recurrence or metastasis, the ...

Inform future clinical development plans, further establishing elraglusib as a potential backbone therapy in ...

Synovial sarcoma is an aggressive malignant tumor that primarily affects the limbs of teenagers and young adults. While it can be cured if completely ...

Based on the clinical trial findings, Ipsen is withdrawing Tazverik across all indications, including both follicular lymphoma and epithelioid sarcoma, and is discontinuing all active tazemetostat ...

Dedifferentiated liposarcoma lacks effective IGF-1→PPAR-γ adipogenic signaling due to epigenetic silencing of PPAR-γ2, with ...

Confirmatory trial on tazemetostat suggested a link with secondary hematologic malignancie ...

The first engineered cell therapy has come to the fight against solid tumors. Fox Chase Cancer Center has begun using Tecelra, an FDA-approved treatment for synovial sarcoma.